Rhythm Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€133.31M - Cost of goods sold
€14.33M - Gross profit
€118.97M - SG&A expenses
€135.23M - R&D expenses
€135.09M - EBITDA
-€139.04M - D&A
€1.31M - EBIT
-€151.35M - Interest expenses
€18.69M - EBT
-€156.16M - Tax expenses
-€14.50K - Net income
-€157.28M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€7.68M - Changes in working capital
€12.40M - Operating cash flow
-€91.88M - Capex
-€34.12M - Other investing cash flow
€0.00 - Net investing cash flow
€7.84M - Total cash dividends paid
-€2.28M - Issuance of common stock
€39.09M - Debt repayment
€0.00 - Other financing cash flow
€30.64M - Net financing cash flow
€61.78M - Foreign exchange effects
€79.32K - Net change in cash
-€21.80M - Cash at end of period
€116.10M - Free cash flow
-€126.00M
Balance sheet
- Cash and cash equivalents
€115.65M - Cash and short-term investments
€248.23M - Total receivables
€22.28M - Inventory
€16.10M - Other current assets
€21.03M - Total current assets
€307.64M - Property, plant & equipment
€3.04M - Goodwill
€0.00 - Intangible assets
€4.90M - Long-term investments
€0.00 - Other non-current assets
€2.34M - Total non-current assets
€10.28M - Total assets
€317.92M - Accounts payable
€13.63M - Short-term debt
€435.01K - Other current liabilities
€96.35M - Total current liabilities
€110.42M - Long-term debt
€3.14M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€90.42M - Total non-current liabilities
€93.56M - Total liabilities
€203.98M - Common stock
€54.59K - Retained earnings
-€1.07B - Other equity
-€1.92M - Total equity
€113.94M - Total liabilities and shareholders' equity
€317.92M
Company information
- Market capitalization
€3.40B - Employees
283 - Enterprise Value
€3.91B
Company ratios
- Gross margin
-
89.2% Much better than peer group: -398.0% - EBITDA margin
-
-104.3% Much better than peer group: -5,976.1% - EBIT margin
-
-113.5% Much better than peer group: -6,479.8% - EBT margin
-
-117.1% Much better than peer group: -5,965.5% - Net margin
-
-118.0% Much better than peer group: -5,912.5% - ROE
-
-138.0% Much worse than peer group: -38.1% - ROA
-
-49.5% Even with peer group: -53.9% - Asset turnover
-
41.9% Much better than peer group: 5.5% - FCF margin
-
-43.3% Much better than peer group: -4,948.1% - FCF yield
-1.7% - Efficiency ratio
204.3% - Net sales per employee
-
€471.04K - Net income per employee
-
-€555.75K